Anti-VEGF-induced hypertension and cancer outcomes: translating research into clinical practice

References

• Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130(4):691–703.
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549–580.
   PubMed Web of Science ®Google Scholar
• Thanigaimani S, Kichenadasse G, Mangoni AA. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol. 2011;9(3):358–380.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–882.
   PubMed Web of Science ®Google Scholar
• Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol. 2003;50(1):49–59.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591.
   PubMed Web of Science ®Google Scholar
• Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502–508.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J. 2001;15(2):427–438.
   PubMed Web of Science ®Google Scholar
• Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract. 2011;2011:816897.
   PubMedGoogle Scholar
• Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807–815.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191.
   PubMed Web of Science ®Google Scholar
• Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250–6257.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–4218.
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28(6):949–954.
   PubMed Web of Science ®Google Scholar
• Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29:95.
   PubMed Web of Science ®Google Scholar
• Dewdney A, Cunningham D, Barbachano Y, et al. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2012;106(11):1718–1721.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Douglas PS, Middleton JP, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18(3):273–280.
   PubMed Web of Science ®Google Scholar
• Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:306.
   PubMed Web of Science ®Google Scholar
• Koyama N. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab. Cancer Biomark. 2014;14(4):259–265.
   PubMed Web of Science ®Google Scholar
• Chen C, Sun P, Ye S, et al. Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis. J Buon. 2014;19(4):917–924.
   PubMed Web of Science ®Google Scholar
• Zhong J, Ali AN, Voloschin AD, et al. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer. 2015;121(9):1456–1462.
   PubMed Web of Science ®Google Scholar
• Robinson ES, Khankin EV, Karumanchi SA, et al. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591–601.
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233–1242.
   PubMed Web of Science ®Google Scholar
• Mir O, Dumont S, Armand JP. Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works? Ann Oncol. 2015;26(7):1277–1278.
   PubMed Web of Science ®Google Scholar
• Mangoni AA. Diastolic and pulse pressure: the old and the new? Hypertension. 2004;43(3):531–532.
   PubMed Web of Science ®Google Scholar
• Head GA, McGrath BP, Mihailidou AS, et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens. 2012;30(2):253–266.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15.
   PubMed Web of Science ®Google Scholar
• Muntner P, Whittle J, Lynch AI, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study. Ann Intern Med. 2015;163(5):329–338.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636–646.
   PubMed Web of Science ®Google Scholar
• McEniery CM, Cockcroft JR, Roman MJ, et al. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35(26):1719–1725.
   PubMed Web of Science ®Google Scholar
• McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471–2479.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Kichenadasse G, Rowland A, et al. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF targeted therapy: a pooled secondary analysis of clinical trials. Int J Cancer. 2016;138(9):2293–2299.
   PubMed Web of Science ®Google Scholar